GPCR-Mediated EGFR Transactivation Ameliorates Skin Toxicities Induced by Afatinib

Researchers examined the ability of three different G-protein-coupled receptor (GPCR) agonists to reverse signaling inhibition and ameliorate rash induced by epidermal growth factor receptor inhibitors (EGFRi).